Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists

MLA

Yongfeng Wu, et al. “Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.” Current Molecular Pharmacology, vol. 11, no. 2, June 2017. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ae17618f11273041f5133de3d15ef432&authtype=sso&custid=ns315887.

APA

Yongfeng Wu, David Massiello, Kaijin Wu, Elizabeth Melendez, Goar Smbatyan, Yi Zhao, & Michael Kahn. (2017). Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists. Current Molecular Pharmacology, 11(2).

Chicago

Yongfeng Wu, David Massiello, Kaijin Wu, Elizabeth Melendez, Goar Smbatyan, Yi Zhao, and Michael Kahn. 2017. “Characterization of Imatinib Resistant CML Leukemic Stem/Initiating Cells and Their Sensitivity to CBP/Catenin Antagonists.” Current Molecular Pharmacology 11 (2). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....ae17618f11273041f5133de3d15ef432&authtype=sso&custid=ns315887.